Form 13-F position report

INOVIO PHARMACEUTICALS INC

Reported by MORGAN STANLEY

INO CUSIP 45773H409 Manager CIK 0000895421

Reported 63,864 shares, down 41,964 (39.7%) from the prior quarter.

Reported value -39.7%; share count -39.7% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q1 2026
Shares 63,864 Quarter-end amount reported
Reported value $111,125 Fair value at quarter end
Consecutive quarters held 52 Through Q1 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 5280000
2021-12-31 2623000
2022-03-31 5939000
2022-06-30 4717000
2022-09-30 2228000
2022-12-31 1961669
2023-03-31 425395
2023-06-30 168186
2023-09-30 118349
2023-12-31 276265
2024-03-31 0
2024-03-31 955971
2024-06-30 837946
2024-09-30 549863
2024-12-31 243898
2025-03-31 463970
2025-06-30 817792
2025-09-30 1841053
2025-12-31 184142
2026-03-31 111125
2026-06-30 55283

Quarterly position history

How this manager's reported quarter-end position changed over time.

21 quarters
Quarterly reported position history for INOVIO PHARMACEUTICALS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 50,256 -13,608 (-21.3%) < 0.01% $55,283 2026-08-13
Q1 2026 Reduced 63,864 -41,964 (-39.7%) < 0.01% $111,125 2026-05-15
Q4 2025 Reduced 105,828 -680,946 (-86.5%) < 0.01% $184,142 2026-02-13
Q3 2025 Added 786,774 +384,912 (95.8%) < 0.01% $1,841,053 2025-11-14
Q2 2025 Added 401,862 +117,219 (41.2%) < 0.01% $817,792 2025-08-15
Q1 2025 Added 284,643 +151,366 (113.6%) < 0.01% $463,970 2025-05-15
Q4 2024 Added 133,277 +38,145 (40.1%) < 0.01% $243,898 2025-02-14
Q3 2024 Reduced 95,132 -8,574 (-8.3%) < 0.01% $549,863 2024-11-14
Q2 2024 Added 103,706 +34,832 (50.6%) < 0.01% $837,946 2024-08-14
Q1 2024 New 68,874 +68,874 (0.0%) < 0.01% $955,971 2024-05-15
Q1 2024 Reduced 0 -541,696 (-100.0%) 0 $0 2024-05-15
Q4 2023 Added 541,696 +237,459 (78.1%) < 0.01% $276,265 2024-02-13
Q3 2023 Reduced 304,237 -72,440 (-19.2%) < 0.01% $118,349 2023-11-15
Q2 2023 Reduced 376,677 -142,099 (-27.4%) < 0.01% $168,186 2023-08-14
Q1 2023 Reduced 518,776 -738,703 (-58.7%) < 0.01% $425,395 2023-05-15
Q4 2022 Reduced 1,257,479 -34,765 (-2.7%) < 0.01% $1,961,669 2023-02-14
Q3 2022 Reduced 1,292,244 -1,434,139 (-52.6%) < 0.01% $2,228,000 2022-11-14
Q2 2022 Added 2,726,383 +1,072,227 (64.8%) < 0.01% $4,717,000 2022-08-15
Q1 2022 Added 1,654,156 +1,128,676 (214.8%) < 0.01% $5,939,000 2022-05-13
Q4 2021 Reduced 525,480 -211,906 (-28.7%) < 0.01% $2,623,000 2022-02-14
Q3 2021 Reduced 737,386 -92,674 (-11.2%) < 0.01% $5,280,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

116 managers reported INOVIO PHARMACEUTICALS INC for Q1 2026.

Managers reporting INOVIO PHARMACEUTICALS INC in Q1 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Reduced 9,339,614 -507,050 < 0.01% $16,250,928 9 qtrs
JANUS HENDERSON GROUP PLC Unchanged 3,308,406 0 < 0.01% $5,773,168 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC New 2,901,208 +2,901,208 < 0.01% $5,048,102 1 qtr
Boxer Capital Management LLC Reduced 2,370,122 -50,000 0.54% $4,124,012 3 qtrs
D E Shaw & Co Inc Reduced 2,212,819 -18,992 < 0.01% $3,850,305 3 qtrs
ADAR1 Capital Management LLC Reduced 1,470,108 -14,900 0.15% $2,557,988 2 qtrs
MILLENNIUM MANAGEMENT LLC Added 1,410,845 +7,466 < 0.01% $2,454,870 4 qtrs
Eversept Partners LP New 1,035,360 +1,035,360 0.09% $1,801,526 1 qtr
ADAGE CAPITAL PARTNERS GP L L C Reduced 804,958 -1,748,613 < 0.01% $1,400,627 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 801,504 +32,148 < 0.01% $1,395,687 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2026
Filed
May 15, 2026
Filing type
13F-HR
Position type
COM SHS

Voting authority reported

Sole
47,517
Shared
0
None
16,347

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.